Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (31-40 of 201) with videos related to

Pageof 21
Sort By:
Journal of Neuro-Oncology|July 16, 2014
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot studyAna-Maria Vranceanu, Vanessa L Merker, Scott R Plotkin, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 21, 2016
Laryngeal Manifestations of NeurofibromatosisMatthew R Naunheim, Scott R Plotkin, Ramon A Franco, et al.
Psycho-Oncology|July 23, 2013
Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousnessKelly B Smith, Daphne L Wang, Scott R Plotkin, et al.
Neurology|December 7, 2007
Clinical reasoning: a case of multiple intracerebral hemorrhagesLinda C Wendell, Stefanie H Freeman, Scott R Plotkin, et al.
Journal of Neuro-Oncology|December 2, 2021
A practical guide to neuro-oncology fellowshipL Nicolas Gonzalez Castro, Deborah A Forst, Scott R Plotkin, et al.
Neurosurgery|October 5, 2011
Facial reanimation of patients with neurofibromatosis type 2Kalpesh T Vakharia, Doug Henstrom, Scott R Plotkin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 17, 2013
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patientsScott R Plotkin, Vanessa L Merker, Alona Muzikansky, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2014
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patientsKatherine M Slusarz, Vanessa L Merker, Alona Muzikansky, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2014
Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphomaSoma Sengupta, Tara Benkers, Marisa Blitstein, et al.
The Oncologist|August 29, 2012
Clinical features of schwannomatosis: a retrospective analysis of 87 patientsVanessa L Merker, Sonia Esparza, Miriam J Smith, et al.
Pageof 21

Showing results (31-40 of 201) with videos related to

Sort By:
Pageof 21
Journal of Neuro-Oncology|July 16, 2014
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot studyAna-Maria Vranceanu, Vanessa L Merker, Scott R Plotkin, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 21, 2016
Laryngeal Manifestations of NeurofibromatosisMatthew R Naunheim, Scott R Plotkin, Ramon A Franco, et al.
Psycho-Oncology|July 23, 2013
Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousnessKelly B Smith, Daphne L Wang, Scott R Plotkin, et al.
Neurology|December 7, 2007
Clinical reasoning: a case of multiple intracerebral hemorrhagesLinda C Wendell, Stefanie H Freeman, Scott R Plotkin, et al.
Journal of Neuro-Oncology|December 2, 2021
A practical guide to neuro-oncology fellowshipL Nicolas Gonzalez Castro, Deborah A Forst, Scott R Plotkin, et al.
Neurosurgery|October 5, 2011
Facial reanimation of patients with neurofibromatosis type 2Kalpesh T Vakharia, Doug Henstrom, Scott R Plotkin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 17, 2013
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patientsScott R Plotkin, Vanessa L Merker, Alona Muzikansky, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2014
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patientsKatherine M Slusarz, Vanessa L Merker, Alona Muzikansky, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2014
Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphomaSoma Sengupta, Tara Benkers, Marisa Blitstein, et al.
The Oncologist|August 29, 2012
Clinical features of schwannomatosis: a retrospective analysis of 87 patientsVanessa L Merker, Sonia Esparza, Miriam J Smith, et al.
Pageof 21